Cochrane Review: Combined DTP‐HBV‐HIB vaccine versus separately administered DTP‐HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB)
Authors: Bar‐On Edna S , Goldberg Elad , Fraser Abigail , Vidal Liat , Hellmann Sarah , Leibovici Leonard 
Published: January 2011

Background

Advantages to combining childhood vaccines include reducing the number of visits, injections and patient discomfort, increasing compliance, and optimizing prevention. The World Health Organization recommends that routine infant immunization programs include a vaccination againstHaemophilus influenzatype B (HIB) in the combined diphtheria, tetanus, pertussis (DTP)‐hepatitis B (HBV) vaccination. The effectiveness and safety of the combined vaccine should be carefully and systematically assessed to ensure their acceptability by the community.

Objectives

To compare the effectiveness of combined DTP‐HBV‐HIB vaccine with DTP‐HBV and HIB vaccinations.

Search strategy

We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library2009, issue 1) which contains the Acute Respiratory Infection Group's Specialized Register; MEDLINE (January 1966 to March 2009) and EMBASE (January 1990 to March 2009).

Selection criteria

Randomized or quasi‐randomized controlled trials comparing vaccination with any combined DTP‐HBV‐HIB vaccine, with or without three types of inactivated poliovirus (IPV) or concomitant oral polio vaccine (OPV) in any dose, preparation or time schedule, compared with separate vaccines or placebo, administered to infants aged up to two years.

Data collection and analysis

Two review authors independently inspected references identified by the searches and evaluated them against the inclusion criteria, extracted data and assessed the methodological quality of included trials.

Main results

Meta‐analysis was performed to pool the results of 18 studies. There were no data on clinical outcomes for the primary outcome and all studies used immunogenicity and reactogenicity (adverse events). In two immunological responses the combined vaccine achieved lower responses than the separate vaccines for HIB and HBV. Comparison found little heterogeneity. No significant differences in immunogenicity were found for pertussis, diphtheria, polio and tetanus. Serious adverse events were comparable. Minor adverse events were more common in children given the combined vaccine.

Authors' conclusions

We could not conclude that the immune responses elicited by the combined vaccine were different from, or equivalent to, the separate vaccines. Data for the primary outcome (prevention of disease) were lacking. There was significantly less immunological response for HIB and HBV, and more local reactions in the combined injections. However, these differences rely mostly on one study each. Studies did not use an intention‐to‐treat analysis and we were uncertain about the risk of bias in many of the studies. These results are therefore inconclusive. Studies addressing clinical end‐points whenever possible, using correct methodology and a large enough sample size should be conducted.

Plain Language Summary

Combined DTP‐HBV‐HIB vaccine versus separately administered DTP‐HBV and HIB vaccines for prevention of diphtheria, tetanus, pertussis, hepatitis B andHaemophilus influenzaeB in healthy infants up to two years of age

Childhood vaccinations provide an effective method of protection against many diseases. There are multiple advantages to combining vaccines: reducing the number of visits, injections and patient discomfort, increasing compliance, and optimizing prevention. The World Health Organization recommends that routine infant immunization programs include a vaccination againstHaemophilus influenzae (H. influenza)type B (HIB) in the combined diphtheria, tetanus, pertussis (DTP)‐hepatitis B (HBV) vaccination. The effect of adding a conjugate HIB vaccination to the DTP‐HBV vaccine, compared to a separate injection for preventing these diseases, has yet to be assessed.

The objective of this review was to compare the effectiveness of the combined DTP‐HBV‐HIB vaccine with the separate DTP‐HBV and HIB vaccines. No data on clinical outcomes for the primary outcome was found. All included studies reported only on immunogenicity, defined as antibody concentration responses to tetanus, diphtheria, pertussis, hepatitis B andH. influenzaetype B and reactogenicity, defined as systematic and local adverse events to vaccination.

Eighteen published randomized or quasi‐randomized clinical trials, comparing vaccination with any combined DTP‐HBV‐HIB vaccine with or without three types of inactivated poliovirus (IPV) or concomitant oral polio vaccine (OPV) given in any dose, preparation or time schedule, compared with separate vaccines or placebo, administered to infants aged up to two years, were included. In two immunological responses the combined vaccine achieved lower responses than the separate vaccines for HIB and HBV. No significant differences in immunogenicity were found for pertussis, diphtheria, polio and tetanus. Serious adverse events were comparable. Minor adverse events were more common in children given the combined vaccine.

Overall, the level of evidence provided by the studies was low, and we could not conclude that the immune responses elicited by the combined vaccine are equivalent to the separate injections. The combined vaccine did not result in a significant increase in the incidence of serious adverse events, but caused more minor reactions.